📰 Mendus Ab News
Mendus Ab News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mendus Ab. Real-time updates on events, politics, business and more.
January 8, 2024
Press release Stockholm, Sweden, January 8, 2024 Mendus AB (
November 3, 2023
Press Release Stockholm, Sweden, November 3, 2023 Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in...
September 4, 2023
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: H.C. Wainwright 25th Annual Global Investment Conference New York, USA, September 11-13, 2023 Mendus CEO Erik Manting will participate and present a Company Update at the conference: https://hcwevents.com/annualconference/ Pareto Securities' Annual Healthcare Confer...
June 8, 2023
08.06.2023 - THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, ...
June 8, 2023
The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting (“EGM”) on Monday, 10...
May 25, 2023
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation...
March 31, 2023
During March, the number of shares and votes in Mendus AB (publ) has changed as a result of 1,137,790 new shares being issued to Negma Group upon...
March 7, 2023
07.03.2023 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk ...
December 7, 2022
07.12.2022 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will host a live webcast to review the Company’s most recent clinical results of the ADVANCE II trial in AML maintenance, which ...
December 5, 2022
05.12.2022 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: 64th Annual Society of ...